一种抗精神病新药卡利拉嗪的受体作用模式介绍
|
摘要
本文目的是系统阐述新型抗精神病药卡利拉嗪(cariprazine)的神经受体主要作用模式。抗精神病药物治疗是临床生物干预的重要手段之一,在一定程度上可以影响疾病预后的发展趋势。新型药物的开发始终是科研人员不懈的追求。卡利拉嗪是2015年美国FDA批准上市的新药,有望被引入国内,本文对其进行介绍便于临床医生参考。
The purpose of this paper is to systematically illustrate the main action mode of the neuroreceptors of the new antipsychotic drug cariprazine. Antipsychotic drug therapy is one of the important means of clinical biological intervention, which can affect the development trend of disease prognosis to a certain extent. The development of new drugs has always been the unremitting pursuit of researchers. As a new drug approved by US FDA in 2015, caliprazine is expected to be introduced into China, so its introduction is convenient for clinical reference.
The purpose of this paper is to systematically illustrate the main action mode of the neuroreceptors of the new antipsychotic drug cariprazine. Antipsychotic drug therapy is one of the important means of clinical biological intervention, which can affect the development trend of disease prognosis to a certain extent. The development of new drugs has always been the unremitting pursuit of researchers. As a new drug approved by US FDA in 2015, caliprazine is expected to be introduced into China, so its introduction is convenient for clinical reference.
引文
[1] Kiss B,Horváth A,Némethy Z,et al.Cariprazine (RGH-188),a dopamine D(3) receptor-preferring,D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate:in vitro and neurochemical profile[J].J Pharmacol Exp Ther,2010,333(1):328-340.
[2] Agai-Csongor E,Domány G,Nógrádi K,et al.Discovery of cariprazine(RGH-188):a novel antipsychotic acting on dopamineD3/D2 receptors[J].Bioorg Med Chem Lett,2012,22(6):3437-3440.
[3] Werner FM,Coveňas R.New developments in the management of schizophrenia and bipolar disorder:potential use of cariprazine[J].Ther Clin Risk Manag,2015,20(11):1657-1661.
[4] Caccia S,Invernizzi RW,Nobili A,et al.A new generation of antipsychotics:pharmacology and clinic utility of cariprazine in schizophrenia[J].Ther Clin Risk Manag,2013,8(7):319-325.
[5] Roberts RJ,Findlay LJ,El-Mallakh PL,et al.Update on chizophrenia and bipolar disorder:focus on cariprazine[J].Neuropsychiatr Dis Treat,2016,25(7):1837-1841.
[6] GaoY,Peterson S,Masri B,et al.Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions[J].Pharmacol Res Perspect,2014,3(1):e00073.
[7] Sachs GS,Greenberg WM,Starace A,et al.Cariprazine in the treatment of acute mania in bipolar Ⅰdisorder:a double-blind,placebo-controlled,phaseⅢ trial[J].J Affect Disord,2015,174(11):296-302.
[8] Zimnisky R,Chang G,Gyertyán I,et al.Cariprazine,a dopamine D3-receptor-preferring partial agonist,blocks phencyclidine-induced impairments of working memory,attention set-shifting,and recognition memory in mouse[J].Psychopharmacology(Berl),2013,226(1):91-100.
[9] Alt1?nba K,Guloksuz S,Oral ET,et al.Clinical potential of cariprazine in the treatment of acute mania[J].Psychiatr Danub,2013,25(3):207-213.
[10] Seneca N,Finnema SJ,Laszlovszky I,et al.Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate,cariprazine(RGH-188),in monkey brain measured using positron emission tomography[J].Psychopharmacology(Berl),2011,218(12):579-587.
[11] 高帅,张瑜良,蔡丽莉.阿立哌唑联合奥氮平对精神分裂症患者体质量、糖脂代谢影响的研究[J].四川精神卫生,2015,28(2):127-130.
[2] Agai-Csongor E,Domány G,Nógrádi K,et al.Discovery of cariprazine(RGH-188):a novel antipsychotic acting on dopamineD3/D2 receptors[J].Bioorg Med Chem Lett,2012,22(6):3437-3440.
[3] Werner FM,Coveňas R.New developments in the management of schizophrenia and bipolar disorder:potential use of cariprazine[J].Ther Clin Risk Manag,2015,20(11):1657-1661.
[4] Caccia S,Invernizzi RW,Nobili A,et al.A new generation of antipsychotics:pharmacology and clinic utility of cariprazine in schizophrenia[J].Ther Clin Risk Manag,2013,8(7):319-325.
[5] Roberts RJ,Findlay LJ,El-Mallakh PL,et al.Update on chizophrenia and bipolar disorder:focus on cariprazine[J].Neuropsychiatr Dis Treat,2016,25(7):1837-1841.
[6] GaoY,Peterson S,Masri B,et al.Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions[J].Pharmacol Res Perspect,2014,3(1):e00073.
[7] Sachs GS,Greenberg WM,Starace A,et al.Cariprazine in the treatment of acute mania in bipolar Ⅰdisorder:a double-blind,placebo-controlled,phaseⅢ trial[J].J Affect Disord,2015,174(11):296-302.
[8] Zimnisky R,Chang G,Gyertyán I,et al.Cariprazine,a dopamine D3-receptor-preferring partial agonist,blocks phencyclidine-induced impairments of working memory,attention set-shifting,and recognition memory in mouse[J].Psychopharmacology(Berl),2013,226(1):91-100.
[9] Alt1?nba K,Guloksuz S,Oral ET,et al.Clinical potential of cariprazine in the treatment of acute mania[J].Psychiatr Danub,2013,25(3):207-213.
[10] Seneca N,Finnema SJ,Laszlovszky I,et al.Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate,cariprazine(RGH-188),in monkey brain measured using positron emission tomography[J].Psychopharmacology(Berl),2011,218(12):579-587.
[11] 高帅,张瑜良,蔡丽莉.阿立哌唑联合奥氮平对精神分裂症患者体质量、糖脂代谢影响的研究[J].四川精神卫生,2015,28(2):127-130.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |